Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
Terminated
CymaBay Therapeutics, Inc.
Phase 2
A 12-week, double-blind, randomized, placebo-controlled, Phase 2 study, to evaluate the
effects of two doses of seladelpar/MBX-8025 in subjects with Primary Biliary Cirrhosis (PBC)
and an inadequate response to ursodeoxycholic acid (UDCA)
Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)
Completed
CymaBay Therapeutics, Inc.
Phase 2
An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to
evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis
(PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)
Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects
Completed
CymaBay Therapeutics, Inc.
Phase 1
This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic
(PK) profiles of seladelpar following administration of a single oral dose in subjects with
varying degrees of hepatic impairment (HI) compared to healthy matched control subjects with
normal hepatic function.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
